BRIP1 and hypoparathyroidism-retardation-dysmorphism syndrome: Limited but growing evidence suggests a potential clinical benefit of PARP-inhibitors in patients with one of the classical HRD-associated cancer types, in whom a BRIP1-mutation has been identified.